MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection

Table 1

Patient and disease characteristics.

	HBV infection group ()	HBV-free group ()	value
Age
≥60	9 (30.0%)	20 (39.2%)	0.403
<60	21 (70.0%)	31 (60.8%)
Sex
male	18 (60.0%)	27 (52.9%)	0.537
female	12 (40.0%)	24 (47.1%)
Stage
I/II	12 (40.0%)	23 (45.1%)	0.655
III/IV	18 (60.0%)	28 (54.9%)
IPI
>2	11 (36.7%)	21 (41.2%)	0.688
≤2	19 (63.3%)	30 (58.8%)
Ki-67
>80%	10 (33.3%)	9 (17.6%)	0.108
≤80%	20 (66.7%)	42 (82.4%)
Molecular subtype
GCB	8 (26.7%)	14 (27.5%)	0.939
Non-GCB	22 (73.3%)	37 (72.5%)
Rituximab
Yes	13 (43.3%)	33 (64.7%)	0.061
No	17 (56.7%)	18 (35.3%)
Antivirus therapy
Lamivudine	21 (70.0%)	0	NA
Entecavir	9 (30.0%)	0

NA = no application.